Key facts
- This page summarizes Richard Malamut's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2022, 17:49.
Richard Malamut - 10 Feb 2022 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)
- Reporting relationship
- EVP and Chief Medical Officer
- Issuer ticker
- COLL
- Reported as of
- 10 Feb 2022
- Net transaction value
- -$111,069
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2022, 17:49:23 UTC
- Next SEC filing
- 15 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shirley R. Kuhlmann as Attorney-In-Fact For Richard Malamut
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard Malamut filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 14 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$111,069.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
COLL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +36,750
- Change %
- +39%
- Price
- $0.000000
- Shares after
- 130,308
- Date
- 10 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
COLL
transaction
Common Stock
Award
- Transaction value
- Shares
- +6,256
- Change %
- +4.8%
- Price
- Shares after
- 136,564
- Date
- 10 Feb 2022
- Ownership
- Direct
- Footnotes
- F2
COLL
transaction
Common Stock
Tax liability
- Transaction value
- $78,665
- Shares
- -4,462
- Change %
- -3.3%
- Price
- $17.63
- Shares after
- 132,102
- Date
- 10 Feb 2022
- Ownership
- Direct
- Footnotes
- F3
COLL
transaction
Common Stock
Tax liability
- Transaction value
- $32,404
- Shares
- -1,838
- Change %
- -1.4%
- Price
- $17.63
- Shares after
- 130,264
- Date
- 10 Feb 2022
- Ownership
- Direct
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
Footnote F2
On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 6,256 performance share units granted in the issuer's two prior fiscal years.
Footnote F3
Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
Footnote F4
Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.